All News
Filter News
Found 2,929 articles
-
The company’s proprietary CRISPR-Cas tech platform is used to selectively and precisely eradicate target bacterial, but still leave the patient’s microbial community alone.
-
Following last year’s stellar initial public offering in October, where it raised $80.5 million, about $10 million over initial expectations, LogicBio Therapeutics is planning a gene-editing clinical trial in children.
-
Beam Therapeutics is one of BioSpace’s NextGen Bio “Class of 2019” Life Science Startups to Watch in 2019.
-
Beam Therapeutics Secures $135 Million in Series B Financing to Advance Base Editing Platform and Expand Pipeline of Precision Genetic Medicines
3/6/2019
Beam Therapeutics today announced the successful completion of a $135 million Series B financing.
-
MassBio® 2019 Annual Meeting, now the State of Possible Conference, Hosts Brightest Minds in Biotech
3/4/2019
MassBio’s Annual Meeting, now the State of Possible Conference, is the premier east coast life sciences conference.
-
MilliporeSigma Awarded Canadian CRISPR Nickase Patent for Foundational Genome-Editing Technology
3/4/2019
MilliporeSigma, a leader in genome editing, today announced that the Canadian Patent Office has allowed MilliporeSigma's patent application directed to the use of paired CRISPR nickases in eukaryotic cells.
-
CRISPR, the gene editing technique that promises to revolutionize healthcare and medicine, is not perfect. Two new studies, one in mice embryos and the other in rice plants, seem to confirm this.
-
The company will focus on what are dubbed modifier genes. Essentially, two people with the same disease-causing genetic mutations often show varying degrees of illness, or in some cases, none at all.
-
The San Francisco Business Times recently looked at top alumni from Bay Area incubators. Some of those companies are now brand-name companies like Uber and Reddit. Here’s a look at the biotech companies on their list.
-
CRISPR Therapeutics and Vertex Announce Progress in Clinical Development Programs for the Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001
2/25/2019
CRISPR Therapeutics (NASDAQ:CRSP) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today reviewed recent progress in the clinical development programs for CTX001, an investigational, autologous, CRISPR/Cas9 gene-edited hematopoietic stem cell therapy being evaluated for patients suffering from severe hemoglobinopathies.
-
Gamida Cell Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Company Update
2/25/2019
Recently Presented NAM-NK and NiCord Data at 2019 TCT Annual Meeting Demonstrate Clinical Progress and Potential of Proprietary NAM Expansion Technology
-
The Michael J. Fox Foundation and The Silverstein Foundation for Parkinson's with GBA Grant Nearly $3 Million to Studies into Disease's Most Common Known Genetic Contributor
2/20/2019
The Michael J. Fox Foundation and The Silverstein Foundation for Parkinson's with GBA teamed up on this funding program to leverage resources and streamline review
-
Mustang Bio and Nationwide Children’s Hospital Enter into Exclusive Worldwide License Agreement for Oncolytic Virus (C134) to Treat Glioblastoma Multiforme
2/20/2019
Phase 1 trial underway at the University of Alabama at Birmingham in recurrent glioblastoma multiforme
-
MilliporeSigma Receives First U.S. Patent for Improved CRISPR Genome-Editing Method
2/19/2019
Proxy-CRISPR technology provides solution to improve genome editing and advance new possibilities for research
-
Gamida Cell Announces Agreement with Editas Medicine to Evaluate Use of CRISPR Genome Editing Technology in NAM-NK Cells
2/19/2019
Through this agreement, the companies aim to discover optimized NAM-NK cells that could be used to improve the treatment of hematologic malignancies and solid tumors.
-
Caribou Biosciences Announces Expansion of Scientific Advisory Board
2/12/2019
The newly appointed members will work with current SAB members and Caribou co-founders Jennifer Doudna, PhD and Martin Jinek, PhD.
-
Immigrant Scientists Lead Charge in Understanding Human Biology and Disease - February 7, 2019
2/7/2019
$250,000 in Vilcek Foundation Prizes awarded to Angelika Amon, Amit Choudhary, Jeanne T. Paz, and Mikhail G. Shapiro
-
IDT backs innovative synthetic biology start-ups with grant awards
2/7/2019
Demonstrating its commitment to advocating for synthetic biology research, Integrated DNA Technologies’ (IDT) Synthetic Biology Start-up Grant Program has once again benefited innovative start-ups in their missions to impact sustainable manufacturing, human health, and/or humanitarian causes. T
-
Every year, BioSpace analyzes the biotech industry, looking for the hot new biotech startups to watch. Here’s a look at the top 3 companies from the Top 20 Life Science Startups to Watch in the U.S. from 2016.
-
The area is home to numerous well-known players in the pharma industry, including Abbott, Iovance, Gossamer Bio, Crown Biosciences, Illumina, Human Longevity and many, many more.